Lilly Continues Pricing Rhetoric Despite Backlash
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm is in wait-and-see mode as it waits for Jardiance cardiovascular safety benefit labeling and data for Alzheimer's therapy solanezumab.